Abu Sina

Dr. Sina's research is centered on the development of nanotechnologies for applications in liquid biopsy, addressing clinical challenges in medical diagnostics and precision oncology. His expertise spans diverse areas of basic and translational research, encompassing chemistry, molecular biology, nano-biotechnology, liquid biopsy, biosensing, and microfluidics, among others. Notably, his work has pioneered the field of "interfacial biosensing," overcoming limitations associated with existing biosensing techniques.

A standout achievement in his innovative portfolio is the establishment of a DNA nano-signature-based cancer test, widely acknowledged as the 10-minute universal cancer test. This groundbreaking development has garnered extensive coverage in major global news outlets, including CNN, Forbes, The Guardian, CTV News, Smithsonian Magazine, and the New York Post. CNN and BioScope, an online magazine, have recognized his discovery of the 10-minute cancer test as one of the "Top Discoveries/Advances for 2018."

Throughout his research career, marked by 52 publications (12 as the First author and 16 as the corresponding author) and a patent (US Patent App. 17286379), Dr. Sina has accumulated 1865 citations, achieving an H-index of 21 and an i10-index of 33 (Source: Google Scholar). His research has been published in high-impact, discipline-ranked journals such as Nature Communications, Accounts of Chemical Research, ACS Nano, Science Advances, and Advanced Functional Materials.

Dedicated to early cancer detection and personalized treatment, Dr. Sina's research program has secured over $1.5 million in grant funding from government agencies and industries. His research outputs rank in the top 25% for citation with an FWCI score >2. The impact is evident through citations in 1,110 documents across 88 countries and in 23 different subject categories (Scopus, Oct 2023). Notably, he has been cited by authors from over 160 institutions, including Harvard Medical School and the University of California.